Polaris has been graced to learn from – and work with – a multitude of innovators within the fields of precision medicine and behavioral health. One revolutionary thinker we’re proud to feature as a member of our team is Dr. Florian Holsboer, our Scientific Advisor & patent co-inventor alongside Dr. Rachel Yehuda. We have immense gratitude for Dr. Holsboer’s significant scientific discoveries as he has progressed humanity toward a deeper understanding of mental and behavioral health, giving rise to our ability to harness these findings and create advancements in therapy and treatment.
Dr. Holsboer studied chemistry & medicine at the Ludwig-Maximilians University of Munich (with dissertations in physical chemistry & biomedical analysis). After training in psychiatry and neurology, he received board certification in 1983, obtained postdoctoral lecture qualification (Habilitation) in 1984, & was appointed Chair of the Department of Psychiatry at the University of Freiburg in 1987. After 25 years at the helm of the Max Planck Institute of Psychiatry in Munich, he left in 2014 to become CEO of the biopharmaceutical company HMNC Brain Health. An internationally-renowned depression researcher & one of the most cited scientists worldwide, Dr. Holsboer is the author or co-author of over 1200 scientific publications. He is known for his discoveries about the connections between stress, depression, anxiety, & sleep disorders, as well as the laboratory diagnostic characterization of these diseases & their best targeted treatments. He is one of the pioneers of personalized depression therapy, which integrates laboratory diagnostics to optimize individual depression treatment plans.
Dr. Holsboer has received numerous awards, including the Gay Lussac Humboldt Prize (France), the Luis Federico Leloir Prize (Argentina), the Freedom to Discover Award (USA), the Wagner v. Jauregg Medal (Austria), the Anna Monika Price, the Robert Pfleger Research Prize, & the Zülch Prize (all Germany). He holds honorary doctorates from the Universities of Leiden (Holland) and Zurich (Switzerland). As of January 2021, he is a member of the Supervisory Board of HMNC Holding GmbH & chairman of the Scientific Advisory Board. He is also Chairman of the Board of Directors of DJE Finanz AG, a Swiss asset management company.
Learn more about Polaris Genomics’s executive team and advisors as well as our lab, support and creative teams at The People of Polaris.